Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology - Wikidata - awgldk - TriplyDB

Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology

Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology

http://www.wikidata.org/entity/Q28389823

about

Immunotherapy for tuberculosis: future prospects Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses Novel adjunctive therapies for the treatment of tuberculosis A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis Persistent high mortality in advanced HIV/TB despite appropriate antiretroviral and antitubercular therapy: an emerging challenge Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model Adjunctive TNF inhibition with standard treatment enhances bacterial clearance in a murine model of necrotic TB granulomas A Subset of Protective γ9δ2 T Cells Is Activated by Novel Mycobacterial Glycolipid Components New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics Etanercept exacerbates inflammation and pathology in a rabbit model of active pulmonary tuberculosis Tuberculosis, pulmonary cavitation, and matrix metalloproteinases.The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells.Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives.Spontaneous latency in a rabbit model of pulmonary tuberculosis.Adjunctive Phosphodiesterase-4 Inhibitor Therapy Improves Antibiotic Response to Pulmonary Tuberculosis in a Rabbit Model.Molecular immunologic correlates of spontaneous latency in a rabbit model of pulmonary tuberculosis.Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment Pharmacologic Inhibition of Host Phosphodiesterase-4 Improves Isoniazid-Mediated Clearance of Mycobacterium tuberculosis.Tumor necrosis factor neutralization combined with chemotherapy enhances Mycobacterium tuberculosis clearance and reduces lung pathology.Macrophages in tuberculosis: friend or foe.Protective role of andrographolide in bleomycin-induced pulmonary fibrosis in mice.Host-directed therapeutics for tuberculosis: can we harness the host?Chemokines in tuberculosis: the good, the bad and the ugly.Host-Directed Therapies for Tuberculosis.Phosphodiesterase inhibitors as adjunctive therapies for tuberculosis.Perspectives for Developing New Tuberculosis Vaccines Derived from the Pathogenesis of Tuberculosis: I. Basic Principles, II. Preclinical Testing, and III. Clinical Testing.Chronic pulmonary cavitary tuberculosis in rabbits: a failed host immune response.Host-Directed Therapeutic Strategies for Tuberculosis.Lentinula edodes β-glucan enriched diet induces pro- and anti-inflammatory macrophages in rabbit.Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials.Harnessing the mTOR Pathway for Tuberculosis Treatment.Tuberculosis and lung damage: from epidemiology to pathophysiology.The wide utility of rabbits as models of human diseases.The Immune Mechanisms of Lung Parenchymal Damage in Tuberculosis and the Role of Host-Directed Therapy

P2860

Q26741261-07178F62-A8B1-43D1-9FD8-BF219EECECF6 Q26823503-9509CDE8-9AB2-4C9F-99CB-342CCBB54849 Q26829957-B7F4F870-4E6C-46CC-B363-345011B66D1F Q27004482-495099C4-53C5-4226-A2B1-F332E4E26C54 Q28088557-580F4BC2-A91C-42F5-AF9E-FCF4E6DF4B2E Q28480511-32211EBB-1A80-4740-BE42-38AF1E87E6D4 Q28480761-5DE04346-2120-4D0E-A34F-033E501C2D45 Q28829233-090408DD-25EC-422C-9AC8-AFB296961C36 Q30371980-B4EDA1FA-545E-4082-9F2B-8E3DE3880DA7 Q34113978-42DAB2CD-182E-48D7-9318-8221F7EE44D7 Q34480272-3DC8F828-8624-4173-96DF-FC61FB3CFD09 Q35125060-5F7C9FB2-569F-4815-97FD-93A800DC688D Q35743972-5960F349-D612-428A-90F7-77E4F959CE3A Q36355577-0F383F3E-D4C6-4FA9-B6F3-437A41F6A36D Q36645097-0D2A9250-8957-4792-B29F-29BEA441555B Q36688480-CD6EA46C-EA6C-4A46-A146-736666BCE566 Q36974934-52B0EC7C-9C81-45DC-9C8F-B1EF1876186C Q37014319-B31CFC46-1422-4074-9B22-154F2EBA5D2E Q37021677-13A35494-1ED6-4716-B785-45BE77ED9920 Q37147624-2ABA11C6-E034-42D3-A3E6-6F0E9A7E1CFF Q37420861-83FB4E86-4402-41C5-867D-2489B1893CA1 Q38168037-F265813B-5A66-4AD0-8FCC-7F6616F6B902 Q38274693-C029B86A-8E10-48C4-9BE5-1FF5DB0BF9F1 Q38489473-FF78D11B-3EE5-4607-90BF-F032FB8837DB Q38746059-70A7943A-91BB-4232-9E75-0F2EECF6E9B4 Q40568831-7BBF1A4D-B471-4CED-B1DF-CAAC46033999 Q42163682-32D5F81F-87AC-4747-8294-A2C6BEA2E6CA Q45006012-E051E38B-1188-4EAC-898B-78EE6429035B Q47152127-ADF9D62F-4F00-41F7-8C21-DA607337DF3C Q48171420-254F6D9B-140F-487B-8AC5-99DDAFEBB49C Q49417693-7E17827D-FF07-460E-8523-C53C289E309B Q54264691-086F7348-2A66-41E9-9E6D-A32B9319604B Q55250836-740EA89E-E909-4EBE-A99C-FC9E5BE14B79 Q58693717-5EB2085F-E5EE-43BF-9B2E-FFAA2739F6C3

P2860

Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology

http://www.wikidata.org/entity/Q28389823

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Phosphodiesterase-4 inhibition ...... activation and lung pathology

@ast

Phosphodiesterase-4 inhibition ...... activation and lung pathology

@en

Phosphodiesterase-4 inhibition ...... activation and lung pathology

@nl

type

label

Phosphodiesterase-4 inhibition ...... activation and lung pathology

@ast

Phosphodiesterase-4 inhibition ...... activation and lung pathology

@en

Phosphodiesterase-4 inhibition ...... activation and lung pathology

@nl

prefLabel

Phosphodiesterase-4 inhibition ...... activation and lung pathology

@ast

Phosphodiesterase-4 inhibition ...... activation and lung pathology

@en

Phosphodiesterase-4 inhibition ...... activation and lung pathology

@nl

P1433

Q28389823-FBA817A1-667C-4518-A701-92CDCDB51D22

P1476

Q28389823-1EBA20FD-C2AC-41AF-9CBF-96EFC43F1D3B

P2093

Q28389823-02D53A75-1195-4C57-8B22-D09DDAF9B22E

Q28389823-7CE3AD1D-788E-42D3-BDD5-877F8E2BAB3C

Q28389823-8DEA1671-7280-4B5D-B0D4-C9F7185794C8

Q28389823-979B6F89-F5BC-416E-840E-80B3370D3906

Q28389823-999D37F7-119C-4676-8C2E-640F50110376

Q28389823-D597CB69-05ED-44FD-8C19-2FC250469EEA

Q28389823-E9F94DF3-888B-4D9C-9F71-0638447D7F70

Q28389823-EB0AC4CE-402E-4314-AA99-A79FFAB1E3C2

Q28389823-F709058F-3286-45DE-8074-F72656E4D6D7

P2860

Q28389823-00F15493-1049-4701-A2BF-D3515FA500C2

Q28389823-047DA129-254D-46AC-8BB4-7CA1F0F9B7D1

Q28389823-0A7689CD-0325-466D-A1E3-94200CB9B7B2

Q28389823-0A8BBEE2-D1C9-4B57-944C-7504612E1A68

Q28389823-114813B3-D32B-4828-BC0E-DD87A785955A

Q28389823-1196C8E2-1366-4A30-BAF4-D51C929CF747

Q28389823-1388C0A2-9A2D-437D-8667-9AB0CC7C20C6

Q28389823-15D9DC02-3C65-4E6D-8A81-8B37121E9156

Q28389823-185E0E02-7FFE-4322-AA71-B0D6B25F2FB4

Q28389823-1A402872-DE70-46ED-BD3A-2163B8E2C7C1

P304

Q28389823-1B7E691B-1935-47C4-8689-F85CDD7B00F5

P31

Q28389823-F9B1D53D-8A5B-4D49-9DF8-75BC6D486993

P3181

Q28389823-4FF71F32-E91A-4EE6-883B-7A1A2773FAB4

P356

Q28389823-01612689-8707-4633-ACEA-AE983A466F32

P407

Q28389823-57A4B59B-951A-4679-99C5-861B788FA8B6

P433

Q28389823-89E0C8BD-F4AD-4A9C-8181-A6BFAEA871A0

P478

Q28389823-A420C939-6537-4BC2-A1BB-9D3F3820414C

P50

Q28389823-A7036499-3098-4421-9799-C6C442ADEA6A

P577

Q28389823-EB87AC84-9F75-41DB-BEF2-569C93476D01

P5875

Q28389823-AFBCE69A-C927-46F7-9DEC-6905F17B36A1

P698

Q28389823-C8C58443-4DD9-45AD-B199-7209CF90A988

P921

Q28389823-37986EC7-5464-4875-B3BD-30C7F792A99D

Q28389823-7d4a7aed-db54-4057-8247-19ac82b996cc

Q28389823-B5326AE5-0B29-4529-894C-24D9107A3D68

P932

Q28389823-DB4ED5F9-7AC7-4250-AD75-569BC9DE7B57

P3181

P356

J.AJPATH.2011.03.039

P1433

The American Journal of Pathology

P1476

Phosphodiesterase-4 inhibition ...... activation and lung pathology

@en

P2093

Blas Peixoto

http://www.w3.org/2001/XMLSchema#string

Dorothy Fallows

http://www.w3.org/2001/XMLSchema#string

George Muller

http://www.w3.org/2001/XMLSchema#string

Guibin Yang

http://www.w3.org/2001/XMLSchema#string

Jerome B Zeldis

http://www.w3.org/2001/XMLSchema#string

Liana Tsenova

http://www.w3.org/2001/XMLSchema#string

Mi-Sun Koo

http://www.w3.org/2001/XMLSchema#string

Paul O'Brien

http://www.w3.org/2001/XMLSchema#string

Selvakumar Subbian

http://www.w3.org/2001/XMLSchema#string

P2860

Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment

Excess lung function decline in gold miners following pulmonary tuberculosis

PDE4 inhibitors: current status

Alternative activation of macrophages

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity

Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice

Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice

Pleural tuberculosis in patients with early HIV infection is associated with increased TNF-alpha expression and necrosis in granulomas

Mycobacterium tuberculosis upregulates microglial matrix metalloproteinase-1 and -3 expression and secretion via NF-kappaB- and Activator Protein-1-dependent monocyte networks.

P304

289-301

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

693308

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.AJPATH.2011.03.039

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

179

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51248128

http://www.w3.org/2001/XMLSchema#string

P698

21703411

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

3123788

http://www.w3.org/2001/XMLSchema#string